Sisram Medical Beheer
Beheer criteriumcontroles 2/4
De CEO Sisram Medical is Lior Dayan, benoemd in Jun2017, heeft een ambtstermijn van 7.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.53M, bestaande uit 56.6% salaris en 43.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.2% van de aandelen van het bedrijf, ter waarde HK$ 3.34M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 7.3 jaar.
Belangrijke informatie
Lior Dayan
Algemeen directeur
US$1.5m
Totale compensatie
| Percentage CEO-salaris | 56.6% |
| Dienstverband CEO | 7.4yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 1.8yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
What Sisram Medical Ltd's (HKG:1696) 40% Share Price Gain Is Not Telling You
Oct 07
Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?
Aug 23Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Just Yet
Jul 24Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)
Jun 17Returns On Capital At Sisram Medical (HKG:1696) Have Stalled
Apr 21Does Sisram Medical (HKG:1696) Have A Healthy Balance Sheet?
Mar 28Estimating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)
Mar 05Take Care Before Diving Into The Deep End On Sisram Medical Ltd (HKG:1696)
Jan 23Is Sisram Medical Ltd (HKG:1696) Potentially Undervalued?
Dec 29Is Sisram Medical (HKG:1696) Using Too Much Debt?
Nov 09Returns On Capital At Sisram Medical (HKG:1696) Have Stalled
Oct 19At HK$6.71, Is It Time To Put Sisram Medical Ltd (HKG:1696) On Your Watch List?
Sep 18Sisram Medical (HKG:1696) Is Paying Out A Larger Dividend Than Last Year
Aug 14Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?
Jun 16Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue
May 30Is Sisram Medical (HKG:1696) Using Too Much Debt?
Apr 19Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?
Mar 01Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital
Jan 12Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet
Dec 21Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?
Dec 01Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital
Oct 14Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching
Sep 28These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely
Aug 25Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?
Aug 01These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely
May 19Is Sisram Medical Ltd (HKG:1696) Trading At A 29% Discount?
May 03If You Like EPS Growth Then Check Out Sisram Medical (HKG:1696) Before It's Too Late
Apr 11Sisram Medical (HKG:1696) Is Experiencing Growth In Returns On Capital
Mar 17Is Now An Opportune Moment To Examine Sisram Medical Ltd (HKG:1696)?
Nov 22Calculating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)
Aug 22Be Wary Of Sisram Medical (HKG:1696) And Its Returns On Capital
Jul 27Here's Why We Think Sisram Medical Ltd's (HKG:1696) CEO Compensation Looks Fair
Jun 24Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$24m |
| Mar 31 2024 | n/a | n/a | US$28m |
| Dec 31 2023 | US$2m | US$863k | US$31m |
| Sep 30 2023 | n/a | n/a | US$35m |
| Jun 30 2023 | n/a | n/a | US$38m |
| Mar 31 2023 | n/a | n/a | US$39m |
| Dec 31 2022 | US$3m | US$1m | US$40m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$35m |
| Mar 31 2022 | n/a | n/a | US$33m |
| Dec 31 2021 | US$2m | US$767k | US$31m |
| Sep 30 2021 | n/a | n/a | US$28m |
| Jun 30 2021 | n/a | n/a | US$24m |
| Mar 31 2021 | n/a | n/a | US$19m |
| Dec 31 2020 | US$769k | US$596k | US$13m |
| Sep 30 2020 | n/a | n/a | US$13m |
| Jun 30 2020 | n/a | n/a | US$13m |
| Mar 31 2020 | n/a | n/a | US$17m |
| Dec 31 2019 | US$759k | US$606k | US$21m |
| Sep 30 2019 | n/a | n/a | US$22m |
| Jun 30 2019 | n/a | n/a | US$24m |
| Mar 31 2019 | n/a | n/a | US$23m |
| Dec 31 2018 | US$884k | US$560k | US$22m |
| Sep 30 2018 | n/a | n/a | US$18m |
| Jun 30 2018 | n/a | n/a | US$14m |
| Mar 31 2018 | n/a | n/a | US$12m |
| Dec 31 2017 | US$829k | US$361k | US$11m |
Compensatie versus markt: De totale vergoeding ($USD 1.53M ) Lior } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 359.96K ).
Compensatie versus inkomsten: De vergoeding van Lior is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Lior Dayan (54 yo)
7.4yrs
Tenure
US$1,526,000
Compensatie
Mr. Lior Moshe Dayan has been Chief Executive Officer and Executive Director at Sisram Medical Ltd since June 6, 2017 and its President since 2023 and is responsible for its overall and day-to-day manageme...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 8.6yrs | US$27.00k | 0.053% HK$ 890.0k | |
| President | 7.4yrs | US$1.53m | 0.20% HK$ 3.3m | |
| Chief Financial Officer | less than a year | geen gegevens | geen gegevens | |
| Chief Operating Officer | 6.6yrs | geen gegevens | geen gegevens | |
| VP of Finance | 1.8yrs | geen gegevens | geen gegevens | |
| Chief Information Officer | less than a year | geen gegevens | geen gegevens | |
| Chief Marketing Officer | 1.8yrs | geen gegevens | geen gegevens | |
| Chief People Officer | 1.8yrs | geen gegevens | geen gegevens | |
| President of ROW | 1.8yrs | geen gegevens | geen gegevens | |
| EVP of R&D | 1.8yrs | geen gegevens | geen gegevens | |
| President NA | 1.8yrs | geen gegevens | geen gegevens | |
| Company Secretary | 2.8yrs | geen gegevens | geen gegevens |
1.8yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 1696 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 8.6yrs | US$27.00k | 0.053% HK$ 890.0k | |
| President | 7.4yrs | US$1.53m | 0.20% HK$ 3.3m | |
| Independent Non-Executive Director | 7.3yrs | US$32.00k | geen gegevens | |
| Non-Executive Director | 8.1yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 7.3yrs | US$32.00k | geen gegevens | |
| Independent Non-Executive Director | 7.3yrs | US$32.00k | geen gegevens | |
| Independent Non-Executive Director | 7.3yrs | US$32.00k | geen gegevens | |
| Non-Executive Director | 4.3yrs | geen gegevens | geen gegevens |
7.3yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 1696 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).